Glycomic Therapeutics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), and Mode of Action [Inhibits Neuraminidase; Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate; Erythropoietin & Enzyme Replacement Therapy (ERT); Tissue Plasminogen Activator; Inhibits Glucosylceramide Synthase; Interleukin 1, 2 & 3; Beta & Gamma Interferons; and Others]

The glycomic therapeutics market is expected to grow from US$ 99,021.46 million in 2021 to US$ 257,578.79 million in 2028; it is estimated to grow with a CAGR of 15.8% from 2022 to 2028.

The report highlights prevailing trends and factors driving the market growth. Glycomics focuses on the structures and functions of complex carbohydrates, as found in glycoproteins, glycolipids, and glycosaminoglycans. Glycans are responsible for much of the structural variation in biological systems, and their representation on cell surfaces is commonly called the “glycome”. These glycans are present in many areas of the microbiome, including cell surfaces and proteins, and can be incredibly complex. Microbial glycomics is poised to revolutionize disease diagnosis, cancer detection, personalized medicine, antimicrobial vaccine, and drug discovery. As therapeutic agents, glycan-integrated nanomaterials can be used as a vaccine against viral and bacterial infections and cancer cells.

The report offers insights and in-depth analysis of the global glycomic therapeutics market, emphasizing various parameters, including market trends, technological advancements, market dynamics, and competitive landscape analysis of global leading market players. It also includes the impact of the COVID-19 pandemic on the market across all regions. The overall impact of the COVID-19 pandemic on the glycomic therapeutics market was mixed; hence, the market is still gaining traction and is expected to grow in the coming years. The health care systems were overburdened, and the delivery of medical care to all patients became a challenge. In addition, the biotechnology industry faced the undesirable impact of the pandemic. During the COVID-19 pandemic, medical device companies found difficulties managing their operations. Many companies of glycomic therapeutics had their business operations in the US, and the pandemic severely affected several businesses. However, after the pandemic restrictions normalized, the volume of surgical procedures returned to normal levels. Gradually hospitals resumed elective procedures as the COVID-19 recovery rate was increasing. The demand for glycan-based drugs in medical therapeutics and vaccine development applications has also increased.

Geography-Based Insights

By geography, the global glycomic therapeutics market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Market Insights

Increasing Research and Development in the Field of Glycomic Therapeutics

Glycans are exceedingly complex and found in many areas of the microbiome components, such as proteins and cell surfaces. Researchers and players are actively involved in the glycomics industry and are constantly focusing on technological developments to offer better alternatives to conventional techniques. A few examples of research & development in the glycomic therapeutics market are mentioned below:

• In February 2022, the National Science Foundation (NSF) awarded ~US$ 23 million to a new multi-university partnership, jointly led by Virginia Tech and the University of Georgia, 2020, to accelerate glycomaterials research in the US. This partnership brought together top scientists and engineers from these institutions, along with Brandeis University, Rensselaer Polytechnic Institute, and the University of North Carolina at Chapel Hill, to establish a national glycomaterials research center.
• In March 2022, Palleon Pharmaceuticals, a company pioneering the field of glycol-immunology to treat cancer and inflammatory diseases, announced the dosing of the first patient in the company’s Phase 1/2 study of E-602 in patients suffering from advanced cancers. The study, called GLIMMER-01 (Glycan-Immune Regulation), is the first clinical study of Palleon’s novel approach to cancer immunotherapy, which targets immunosuppressive sialoglycans.
• In April 2022, CPTAC glycoproteomic researchers developed "Peptide-First" multi-attribute glycan identification method.
• In March 2022, Japanese researchers uncovered the precise mechanism of a beta-1,2-glucan-associated enzyme to provide new information on complicated sugar metabolism. A team of researchers from Niigata University and Tokyo University of Science identified the structure and function of a new enzyme with glycosyltransferase activity. The findings of this investigation were made public on January 19, 2022, and were printed in the Journal of Biological Chemistry, Volume 298, Issue 3.
• According to a study published in February 2022 by researchers at the University of Copenhagen's Center for Glycomics, Heparin can now be produced without using animals through glycomics studies.
• In February 2022, GlycoMIP, a national research hub focused on glycomaterials research and led jointly by Virginia Tech and the University of Georgia, celebrated the grand opening of its national user facility with ribbon-cutting ceremonies at both universities. GlycoMIP will address nationwide bottlenecks in glycomaterial synthesis, computer modeling, material characterization, and knowledge sharing through ground-breaking research and a unique national user facility that will provide critical tools and services to the scientific community.

Such advancements in the field of glycomics propel the glycomic therapeutics market growth significantly.

Class-Based Insights

Based on the class, the glycomic therapeutics market is bifurcated into isolated and synthetic. In 2021, the synthetic segment accounted for a larger market share. However, the isolated segment is expected to register a higher CAGR of 16.3% during the forecast period. 

Structure-Based Insights

Based on structures, the glycomic therapeutics market is segmented into glycoproteins, targeting sialic acid, proteoglycans, targeting glycosaminoglcans, glycophosphatidylinositol (GPI)-anchored proteins & heparin based glycans, targeting glycosphingolipids, and others. The glycoproteins segment held the largest market share in 2021. However, the targeting sialic acid segment is anticipated to register the highest CAGR during the forecast period.

Indication-Based Insights

Based on indication, the glycomic therapeutics market is segmented into thrombosis & chemoprophylaxis, anemia, anti-adhesive & anti-inflammatory, cataract, Gaucher’s diseases, MPS-1 & IV, cancer, Alzheimer’s disease, influenza type A & B, and others. The influenza type A & B segment held the largest market share in 2021, and it is expected to continue a similar trend during the forecast period.

Glycomic Therapeutics Market Regional Insights

The regional trends and factors influencing the Glycomic Therapeutics Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Glycomic Therapeutics Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Glycomic Therapeutics Market Report Scope

Glycomic Therapeutics Market Players Density: Understanding Its Impact on Business Dynamics

The Glycomic Therapeutics Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

Major Companies operating in the Glycomic Therapeutics Market are:

1. Intellihep Ltd
2. Protalix Biotherapeutics
3. BioMarin Pharmaceutical Inc.
4. Genzyme Corporation (Sanofi)
5. Halozyme Therapeutics, Inc.

Disclaimer: The companies listed above are not ranked in any particular order.

Mode of Action-Based Insights

Based on mode of action, the glycomic therapeutics market is segmented into inhibits neuraminidase; inhibits heparanase and selectins and blocks interactions between growth factors and heparan sulfate; erythropoietin & enzyme replacement therapy (ERT); tissue plasminogen activator; inhibits glucosylceramide synthase; interleukin 1, 2 & 3; beta & gamma interferons; and others. In 2021, the erythropoietin & enzyme replacement therapy (ERT) segment held the largest share of the market. However, the inhibits neuraminidase segment is expected to register the highest CAGR during the forecast period.

Intellihep Ltd; Protalix Biotherapeutics; BioMarin Pharmaceutical Inc.; Genzyme Corporation (Sanofi); Halozyme Therapeutics, Inc.; Bayer AG; Alzheon, Inc.; GlycoMar; GlaxoSmithKline plc.; and F. Hoffmann-La Roche Ltd are among the leading players operating in the glycomic therapeutics market. These companies have been implementing various strategies that have helped their growth, resulting in several developments in the market.

The List of Companies - Glycomic Therapeutics Market

1. Intellihep Ltd
2. Protalix Biotherapeutics
3. BioMarin Pharmaceutical Inc.
4. Genzyme Corporation (Sanofi)  
5. Halozyme Therapeutics, Inc.       
6. Bayer AG            
7. Alzheon, Inc.     
8. GlycoMar
9. GlaxoSmithKline plc.      
10. F. Hoffmann-La Roche Ltd 

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the glycomic therapeutics market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the glycomic therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
• Enhancing the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.